Caris Life Sciences, Inc. CAI
Composite 61/100; the shares have moved about 75% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 28/100 — a moderate mark against it.
Growth ranks 98/100 — a strong point in its favour. Balance-sheet strength ranks 77/100 — a strong point in its favour. Quality ranks 70/100 — a moderate point in its favour.
Valuation ranks 28/100 — a moderate mark against it. Momentum ranks 37/100 — a moderate mark against it.
What the company does Caris Life Sciences applies AI-driven molecular profiling—whole exome/transcriptome and genome sequencing—to guide therapy selection and early cancer detection. Its MI Profile, Caris Assure, and Caris Detect platforms serve hospitals and pharma partners, positioning the firm in the TechBio oncology market.
Key financials Revenue grew 78.8% but net margins remain thin at 3.8%. ROE is strong at 28.3%, yet operating margin is just 2.4% and interest coverage is 1.60x. Debt/Equity is 0.73 with a current ratio of 7.05 and FCF yield of 2.3%.
Stock health Momentum is weak: -17.95% over 3m, -38.13% over 6m, and -47.15% over 12m. The stock is -63.32% below its 52-week high and RSI(14) is 40.80, indicating oversold conditions.
Price vs fair value The stock trades at a PREMIUM of 63.20% versus our fair-value estimate of 5.73 and at a discount of 73.19% versus the 12-month target of 27.00. - Valuation percentile 34.0/100 signals rich pricing relative to peers. - EV/EBITDA of 35.90 and P/B of 7.40 reflect high market expectations. - Gross margin of 68.9% supports premium pricing power. - Recent CareDx earnings beat (Zacks) may have shifted investor focus away from CAI.
Looking forward Forward P/E of 40.82 implies high growth expectations. Execution on pharma services and early-detection adoption will be key to justifying current multiples.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.